Week In Review: Tasly Pharma Acquires Sutro ADC In $385 Million Deal
January 01, 2022 at 14:45 PM EST
Tasly Pharma acquired Greater China rights to an antibody-drug conjugate from Sutro Biopharma in a deal worth up to $385 million. Sutro will receive an upfront payment of $40 million and be eligible for $345 million in milestone payments.
